A 56-year-old man is brought to the emergency department by ambulance after vomiting a large amount of bright red blood. He has a history of alcohol use disorder and compensated cirrhosis. On arrival, he is lethargic but localizes to pain and maintains his airway. Blood pressure is 88/55 mm Hg, and pulse is 118/min. Physical examination reveals scleral icterus, palmar erythema, and a distended abdomen with shifting dullness. Two large-bore peripheral intravenous lines are placed, and fluid resuscitation with isotonic crystalloid is initiated. Laboratory studies show:
| Laboratory Parameter | Result |
|---|---|
| Hemoglobin | 8.2 g/dL |
| Platelet count | 75,000/mm³ |
| Prothrombin time | 18 seconds |
| INR | 1.8 |
Which of the following pharmacologic interventions are most appropriate for this patient at this time? (Select all that apply)
- Intravenous octreotideCevap
- Intravenous ceftriaxoneCevap
- CIntravenous propranolol
- DIntravenous fresh frozen plasma
- EEnteral lactulose
Cevap
The most appropriate interventions are intravenous octreotide and intravenous ceftriaxone.
In the setting of suspected acute variceal hemorrhage, initial pharmacologic therapy focuses on reducing portal venous pressure and preventing severe infectious complications. Intravenous octreotide, a somatostatin analog, inhibits the release of vasodilator hormones (such as glucagon), leading to splanchnic vasoconstriction and a subsequent decrease in portal inflow and variceal pressure. Concurrently, bacterial infections (particularly spontaneous bacterial peritonitis) are a major trigger and complication of variceal bleeding in cirrhosis. The administration of prophylactic antibiotics, typically intravenous ceftriaxone, has been definitively shown to reduce both rebleeding rates and overall mortality, making it a mandatory initial intervention.
Adım Adım Çözüm
Anahtar Kavram
The initial pharmacologic management of acute variceal bleeding in cirrhosis requires splanchnic vasoconstrictors (e.g., octreotide) to decrease portal pressure and prophylactic antibiotics (e.g., ceftriaxone) to prevent mortality-increasing infections.